The Complexities of GLP-1 Agonists and Eating Disorders

The increasing use of glucagon-like peptide-1 (GLP-1) agonists, initially designed for managing type 2 diabetes, for weight loss has brought a new set of challenges to the forefront of eating disorder recognition and treatment. What’s being termed “agonorexia” isn’t a new, distinct diagnosis, but rather a complex interplay of existing eating disorder behaviors and psychological responses to these medications. Understanding these nuances is crucial for healthcare professionals and individuals alike.

Understanding “Agonorexia”

The term “agonorexia” describes behaviors and psychological responses that emerge with the use of GLP-1 agonists. It’s not a formal diagnosis listed in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), but a pattern of adaptive responses to the significant appetite suppression these medications induce. The core issue isn’t a new eating disorder, but the exacerbation or manifestation of underlying vulnerabilities and pre-existing disordered eating patterns.

Connections to Established Eating Disorders

Several established eating disorders, as defined in the DSM-5-TR, can be intertwined with the use of GLP-1 agonists:

Anorexia Nervosa

Anorexia nervosa is characterized by persistent restriction of food intake, an intense fear of gaining weight, and a distorted body image [1]. Even as not all GLP-1 agonist users develop anorexia nervosa, the medications’ potent appetite suppression can encourage restrictive behaviors, particularly when patients begin to prioritize the absence of hunger as a sign of control. Onset typically occurs during adolescence, and is rare after age 40 [2].

Binge Eating Disorder (BED)

Binge Eating Disorder (BED) involves recurrent episodes of consuming an abnormally large amount of food accompanied by a sense of loss of control [1]. When discontinuing GLP-1 agonists, some patients experience a rebound effect – a sudden return of physiological hunger – which can trigger episodes of overeating. This can lead to a cycle of fear, guilt, and a desire to resume medication use to regain control.

Beyond Formal Diagnoses: Other Concerning Behaviors

Certain behaviors, while not formally classified as eating disorders in the DSM-5-TR, are relevant in this context:

“Drunkorexia” (Alcoholic Anorexia)

This term describes the practice of substituting food calories with alcoholic beverages. Some patients using appetite suppressants may exhibit this pattern, reducing food intake while maintaining or increasing alcohol consumption, which can compromise nutritional status. This behavior is also observed in individuals post-bariatric surgery.

Adaptation Disorder

Adaptation disorder involves emotional or behavioral symptoms that arise in response to a specific stressor, such as a change in health or routine. Becoming accustomed to the reduced hunger induced by GLP-1 agonists can create anxiety when considering stopping the medication, contributing to the behaviors seen in “agonorexia.”

The Importance of Professional Evaluation

Recognizing these complex interactions requires careful evaluation by professionals specializing in eating behaviors. The DSM-5-TR provides the diagnostic criteria for these disorders [1], allowing for accurate identification of underlying issues. It’s crucial that clinicians do not dismiss these symptoms due to a lack of awareness.

Key Takeaways

• “Agonorexia” is not a new diagnosis, but a set of behaviors related to the use of GLP-1 agonists.
• GLP-1 agonists can exacerbate existing eating disorder vulnerabilities, such as anorexia nervosa and binge eating disorder.
• Behaviors like “drunkorexia” and adaptation disorder can also play a role.
• Professional evaluation is essential for accurate diagnosis and treatment.